Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

<p>Supplementary Figure 1</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Vishwajith Sridharan (15047154) (author)
Andere auteurs:	Azfar Neyaz (15047157) (author), Abhijit Chogule (15047160) (author), Islam Baiev (15047163) (author), Stephanie Reyes (15047166) (author), Emily G. Barr Fritcher (15047169) (author), Jochen K. Lennerz (15014703) (author), William Sukov (15047172) (author), Benjamin Kipp (15047175) (author), David T. Ting (15018716) (author), Vikram Deshpande (15047178) (author), Lipika Goyal (15047181) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Gastrointestinal Cancers Immunotherapy Checkpoint blockade Precision Medicine Translational Research
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary Figures1 from The Ave–Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
door: Michael Michael (15021425)
Gepubliceerd in: (2025)

Figure 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
door: Robert W. Lentz (17013559)
Gepubliceerd in: (2025)

Figure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
door: Robert W. Lentz (17013559)
Gepubliceerd in: (2025)

Figure 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
door: Robert W. Lentz (17013559)
Gepubliceerd in: (2025)

Figure 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
door: Robert W. Lentz (17013559)
Gepubliceerd in: (2025)

Supplementary Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
door: Robert W. Lentz (17013559)
Gepubliceerd in: (2025)

Supplementary Table 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
door: Robert W. Lentz (17013559)
Gepubliceerd in: (2025)

Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
door: Robert W. Lentz (17013559)
Gepubliceerd in: (2025)

Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
door: Robert W. Lentz (17013559)
Gepubliceerd in: (2025)

Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
door: Kohei Shitara (15043443)
Gepubliceerd in: (2025)

Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
door: Kohei Shitara (15043443)
Gepubliceerd in: (2025)

Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
door: Kohei Shitara (15043443)
Gepubliceerd in: (2025)

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
door: Kohei Shitara (15043443)
Gepubliceerd in: (2025)

Table 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
door: Kohei Shitara (15043443)
Gepubliceerd in: (2025)

Table 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
door: Kohei Shitara (15043443)
Gepubliceerd in: (2025)

Table 4 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
door: Kohei Shitara (15043443)
Gepubliceerd in: (2025)

Figure 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
door: Maria Alsina (21718246)
Gepubliceerd in: (2025)

Figure 2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
door: Maria Alsina (21718246)
Gepubliceerd in: (2025)

Figure 3 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
door: Maria Alsina (21718246)
Gepubliceerd in: (2025)

Table 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
door: Maria Alsina (21718246)
Gepubliceerd in: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
door: Ankita Mitra (17141783)
Gepubliceerd in: (2025)

Figure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S10 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S11 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S2 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S5 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S6 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
door: Jiahuan Lu (22247140)
Gepubliceerd in: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
door: Roger Li (17078665)
Gepubliceerd in: (2025)

Figure 1 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients
door: Lauren Polyakov (21672045)
Gepubliceerd in: (2025)

Figure 2 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients
door: Lauren Polyakov (21672045)
Gepubliceerd in: (2025)

Figure 3 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients
door: Lauren Polyakov (21672045)
Gepubliceerd in: (2025)

Figure 4 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients
door: Lauren Polyakov (21672045)
Gepubliceerd in: (2025)